Cihan Ay, MD

Professor, Head of the Thrombosis and Haemostasis Research Group
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria

Presentation(s):

• PB0429 - Impact of venous thromboembolism on physical functioning: Results from a prospective cohort study

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• VPB0419 - Renal function at enrollment but not change over time is associated with arterial thrombotic events in patients positive for lupus anticoagulant

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• VPB0420 - Increased expression of protein disulfide isomerase A1 on platelet surface in lupus anticoagulant-associated thrombosis

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• SS 20.3 - How do you identify which patients with venous thromboembolism are eligible for extended anticoagulation?

  Monday, July 11, 2022
  1:34 PM – 1:46 PM

• OC 45.1 - Circulatory microRNA-411-5p as a novel prognostic biomarker for major adverse cardiac events in patients with atrial fibrillation

  Monday, July 11, 2022
  2:45 PM – 3:00 PM

• PB0499 - Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0500 - Frequency, reasons and duration of hospitalization in patients with end-stage kidney disease on hemodialysis: Prospective results of VIVALDI

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0521 - Use of antithrombotic agents for the prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: Prospective results of the VIVALDI study

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0543 - Extracellular vesicles from human body fluids trigger coagulation directly by exposing functional tissue factor/factor VIIa complexes

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0911 - Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0914 - Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0935 - Plasma MiRNAs and the Risk of Venous Thromboembolism in Patients with Glioblastoma: A Nested Case-control Study

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 52.2 - Risk and impact of anticoagulation-associated abnormal menstrual bleeding in women of reproductive age with venous thromboembolism – the TEAM-VTE study

  Tuesday, July 12, 2022
  11:00 AM – 11:15 AM

• PB1138 - Obesity, fibrinolysis, and bleeding in patients with non-severe hemophilia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1139 - Annualized Bleeding Rates in Severe Hemophilia on Prophylaxis in a Real-World Setting

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1205 - Clinical and laboratory characteristics of adults with immune thrombocytopenia in a contemporary cohort in Austria

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1212 - Platelet desialylation status in adults with primary immune thrombocytopenia

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1241 - Rotational thromboelastometry (ROTEM) in patients with bleeding of unknown cause: evidence for hemostatic imbalance

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1310 - Decreased mitochondrial DNA copy number in patients with history of recurrent venous thromboembolism

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM